Companion Diagnostics in Personalized Medicine and Cancer Therapy

Description: Companion diagnostics (CDx) refers to a particular clinical diagnostic test that is under evaluation and is specifically linked to a known drug therapy. This linkage could be important in the therapeutic application and clinical outcome of a drug, such as with personalized medicine for oncology patients. The molecular diagnostics field plays a vital part in personalized medicine and has greatly expanded over the past twenty years, expanding by more than 20% annually compared to most other laboratory procedures.

Research will continue to produce an increased understanding of disease processes, and diagnostics manufacturers will continue to expand and refine the technology and automation needed for clinical testing. Companion diagnostics, although smaller at present, is one of the fastest growing segments in the in vitro diagnostic (IVD) market. And while the concept of a drug-diagnostic combination is not new, it has only recently started to generate interest with the move of healthcare towards pharmacogenomics.

This report examines the use of companion diagnostics in personalized medicine and cancer therapy. The study provides a qualitative and quantitative review of the industry, including cancer biomarker tests, pharmacogenomics tests, recurrence prediction tests, blood-based technologies, proteomics and regulatory trends.

Moreover, this analysis profiles the leading companies that are developing and manufacturing companion diagnostics solutions. Each company is discussed in extensive depth with a section on its history, product line, business and marketing analysis, and a subjective commentary of the company's market position. Detailed tables and charts with sales forecasts and market share data are also included.

Contents:
1. Overview
   1.1 Statement of Report
   1.2 Why You Should Read This Report
   1.3 Scope of the Report
   1.4 Objectives
   1.5 Key Questions Answered by This Report
   1.6 Methodology
   1.7 Executive Summary

2. Companion Diagnostics: Trends and Overview
   2.1 Stakeholders in Companion Diagnostics
   2.2 Development of Stakeholders’ Business Models for Companion Diagnostics for Personalized Medicine
      2.2.1 Pharmaceutical Company Business Models for Developing Companion Diagnostics Products
      2.2.2 Diagnostic Company Business Models for Developing Companion Diagnostics Products
      2.2.3 Life Science Company Business Models for Developing Companion Diagnostics Products
      2.2.4 Pharmacy Benefit Management Company Business Models for Developing Companion Diagnostics Products
   2.3 Trends in Companion Diagnostic Deals
   2.4 Market Size of Companion Diagnostics
   2.5 Companion Diagnostics: Industry SWOT Analysis
   2.6 Challenges for Companion Diagnostics Development
   2.7 Timeline for Impact of Various Segments in Companion Diagnostics
   2.8 Use of Proteomics to Develop Individualized Tests

3. Companion Diagnostics: Qualitative and Quantitative Market Analysis
   3.1 Market Analysis of Molecular Diagnostics and Companion Diagnostics
   3.2 Costs of Companion Diagnostics in Healthcare Expenditures
   3.3 Molecular Diagnostic Market
   3.4 Molecular Diagnostics Technology Platforms and Their Impact on Clinical Medicine
   3.5 Snapshot of Companion Diagnostics Industry Structure
   3.6 The Case for Theranostics
   3.7 Companion Diagnostics Market Analysis
4. Biomarker Tests Co-Developed with Cancer Therapeutics as Companion Diagnostics

4.1 Sector Overview

4.1.1 Impact of New Technology Platforms

4.1.2 Impact on Drug Discovery

4.1.3 Biomarkers as Endpoints in Drug Discovery

4.1.4 Targeted Therapy

4.2 Companion Diagnostics on the Market

4.3 Epidermal Growth Factor Receptor Companions

4.3.1 Bevacizamab (Avastin)

4.3.2 EGFR for CRC and Camptosar (Irinotecan)

4.3.2.1 Companion Diagnostic Test Developed for UGT1A1 for Irinotecan

4.3.2.2 Companion Diagnostic Test Developed for Bristol-Myers' SPRYCEL

4.3.3 EGFR Express and Erbitux (Cetuximab)

4.3.4 HER2 and Herceptin (Trastuzumab)

4.3.4.1 Siemens' Advia Centaur HER2/neu Assay

4.3.4.2 Companies Marketing HER2/neu Assays

4.3.5 Iressa and Tarceva Companion Test

4.3.6 Tykerb GlaxoSmithKline (GSK) and Vectibix (Amgen) Companion Tests

4.3.7 EGFRx Assay

4.3.8 A Personalized Medicine Program for CML

4.4 Companions Based on Myriad's IVDMA Technology

4.4.1 Myriad's BRACAnalysis Collaboration with Partners in Companion Test Development

4.5 Companions for Tyrosine Kinase Inhibitors: Erlotinib and Gefitinib

4.5.1 TheraScreen: EGFR29

4.5.2 The K-RAS Mutation Detection Kit

4.6 Irinotecan and UGT1A1

4.7 Gleevec (Imatinib) Companions

4.7.1 DakoCytomation's c-Kit (9.7) pharmDx

4.8 Companion Diagnostics Involving Metabolizing Enzymes

4.8.1 Companions for TMPT, CYP2C9 and UGT1A1 Enzymes

4.8.2 Companions for Aromatase Inhibitors

4.9 Drivers and Barriers to Companion Diagnostics

4.10 Partnerships with Pharma Companies to Identify Therapeutic Targets

4.11 Circulating Tumor Cell Assay: Prognostic and Predictive Factors for Breast Cancer

4.12 Companion Diagnostics Used by Clinical Service Laboratories

4.13 New Technologies and Products under Development

4.13.1 MDxHealth Epigenetic Marker as Companion for Irinotecan Therapy in Colorectal Cancer

4.13.2 Ventana to Collaborate with Pfizer and CST on Companion Diagnostic to Identify Lung Cancer Patients with ALK Gene Rearrangements

4.13.3 Abbott and Merck Collaborate to Develop Companion Diagnostic Test for Investigational Cancer Therapy

4.14 Pharmacogenomics Tests

4.14.1 MGMT Methylation Assay

4.14.2 Other Pharmacogenomic Opportunities

4.15 Recurrence Prediction Tests

4.16 Monogram Biosciences HIV Personalized Platform

4.17 Wako LBA AFP Test for Liver Cancer

4.18 Future Developments for Companion Diagnostics

4.19 Drug Response Predictors

5. Business and Regulatory Trends in the Companion Biomarker Testing Sector

5.1 Industry Consolidation

5.2 Breath of Product Offering and Pricing

5.3 Government Regulation of Medical Devices

5.3.1 FDA Guidance on Drug Test Co-Development

5.3.2 Device Classes

5.3.3 Investigational Use of IVDMAIs

5.3.4 Post-Market Requirements

5.3.5 Voluntary vs. Required Submissions

5.3.6 Examples of Recent Voluntary Genomic Data Submissions

5.3.7 FDA Labeling Implications and Rules

5.3.8 Regulatory Activities in Companion Diagnostic Testing-Translation of Diagnostic Testing Results into
Clinical Practice
5.4 Strategic Business and Marketing Considerations
5.5 Commercial Opportunities in Companion Markers
5.6 Moderators of Growth
5.6.1 Roadblocks to Integrating Companion Biomarkers into Clinical Practice
5.6.2 Management of Targeted Therapeutics by Third-Party Payers
5.7 Biotechnology Industry Trends
5.8 Pharmaceutical Industry Trends
5.9 Acquisition, License Agreement, Partnerships
5.10 Legal Developments
5.11 Sales and Marketing Strategies for Companion Diagnostic Tests
5.11.1 International Markets
5.11.2 Europe
5.11.3 Central and South America
5.11.4 Asia-Pacific
5.11.4.1 Japan
5.11.4.2 China
5.12 Product Commercialization
5.13 Reimbursement
5.14 Self-Referral Rules
5.15 Health Insurance Portability and Accountability Act
5.16 Clinical Laboratory Improvement Amendments (CLIA)
5.17 In Vitro Diagnostic Directive (IVDD) and Medical Device Regulations
5.18 FDA's Quality System Regulation (QSR)
5.19 The FDA's OIVD on IVDMIAs
5.20 FDA's Qualification of Cancer Biomarkers
5.20.1 Regulatory Perspectives of Biomarker Validation
5.21 Genetic Tests and Medical Records
5.21.1 Laws Against Genetic Discrimination
5.22 Global Drivers of Clinical Laboratory Testing
5.23 Global Outlook
5.24 Oncology Biomarker Qualification Initiative
5.25 FDA Critical Path
5.26 Biomarkers and FDA's Voluntary Genomic Data Submission
5.27 From Personalized to Predictive Medicine
5.28 Analysis of Cost-Effectiveness at the Individual Level
5.29 The Patient and Advocate Perspective: An Evolution of Influence
5.30 Real-World Experiences Translating the Vision of Personalized Medicine into Practice
5.30.1 Evolving Business Models in Companion Diagnostics and Personalized Medicine
5.30.2 Current Pharma/Diagnostics Business Model Examples
5.31 Reimbursement and Value Creation
5.32 What is the Role of Governmental Agencies in Driving the Adoption of Companion Diagnostics?
5.33 What is the Role of the Insurance Industry in Driving the Adoption of Pharmacogenomics (PGx)?
5.34 What is the Role of the Pharma Industry in Driving the Adoption of PGx?
5.35 FDA Guidance Document on Co-Development
5.36 What is the Role of the Diagnostic Industry in Driving the Adoption of PGx?
5.37 What is the Future Role of PBMs in Laboratory Services?

6. Companion Diagnostics and Personalized Medicine
6.1 Scope of This Section
6.2 Introduction to Companion Diagnostics and Personalized Medicine
6.3 Drug Metabolism, Companion Diagnostics and Personalized Medicine
6.4 Examples of Personalized Medicine and Companion Diagnostic Tests
6.5 Personalized Medicine and Companion Diagnostic Testing Product Pipeline
6.6 The Personalized Medicine Coalition (PMC)
6.7 Regulatory Trends and Guidelines in the Personalized Medicine Space
6.7.1 The Changing Regulatory Landscape for Personalized Medicine
6.8 Companion Diagnostics Play an Increasing Role in Cancer Care
6.9 Specific Examples of Clinical Situations where Companion Diagnostics are being Deployed
6.9.1 Epidermal Growth Factor Receptor Assay
6.9.2 Individualized Warfarin Therapy
6.9.3 UGT1A1 Molecular Assay for Camptosar
6.9.4 Response to Gleevec in Gastrointestinal Stromal Tumors (GISTs)
6.9.5 LabCorp and QIAGEN and Personalized Medicine for the treatment of Colorectal Cancer
6.9.6 LabCorp and ARCA Discovery, Inc. Personalized Medicine for Cardiovascular Disease
6.9.7 Roche's Metastatic Melanoma Treatment, Zelboraf (Vemurafenib)
6.9.8 Abbott's Companion Test for Late-Stage NSCLC Treatment Drug Xalkori (Crizotinib)
6.10 Diagnostic Tests for Personalized Analysis of Cancer Therapy Effectiveness
6.11 Value Chain
6.12 Impact of Companion Diagnostics/Personalized Medicine on Drug Clinical Trials
6.13 The Market Problem: Finding Value with Diagnostics for Personalized Medicine

7. Companies Entering the Companion Diagnostics Market
7.1 Industry Overview
7.1.1 20/20 GeneSystems, Inc.
7.1.2 Abbott Molecular, Inc.
7.1.3 Affymetrix, Inc.
7.1.4 Agendia BV
7.1.5 Agilent Technologies
7.1.6 Almac Group
7.1.7 Asuragen, Inc.
7.1.8 Aureon Laboratories, Inc.
7.1.9 Becton, Dickinson and Company (BD) Diagnostics-TriPath
7.1.10 Biodesix
7.1.11 Biomarker Technologies, LLC
7.1.12 bioMérieux, Inc.
7.1.13 Cepheid, Inc.
7.1.14 Cipher Genomics
7.1.15 diaDexus
7.1.16 DiagnoCure
7.1.17 EDP Biotech Corporation
7.1.18 Eisai Co., Ltd.
7.1.19 Eli Lilly & Co.
7.1.20 Epigenomics
7.1.21 Exagen Diagnostics, Inc.
7.1.22 Exiqon
7.1.23 Genomic Health, Inc.
7.1.24 Hologic
7.1.25 Halozyme Therapeutics
7.1.26 Ikonisys, Inc.
7.1.27 Illumina, Inc.
7.1.28 HalioDx
7.1.29 InterGenetics, Inc.
7.1.30 Johnson & Johnson
7.1.31 LabCorp
7.1.32 MolecularMD Corporation
7.1.33 MDxHealth
7.1.34 Monogram Biosciences
7.1.35 Myriad Genetics, Inc.
7.1.36 Novartis MDx
7.1.37 Nycomed (Takeda)
7.1.38 Orion Genomics
7.1.39 Oxford BioTherapeutics (Formerly Oxford Genome Sciences)
7.1.40 NanoString Technologies
7.1.41 QIAGEN N.V.
7.1.42 Roche Molecular Diagnostics
7.1.43 Sanko Junyaku Co., Ltd. (Eisai Co., Ltd.)
7.1.44 SensiGen, LLC (Sequenom Center for Molecular Medicine)
7.1.45 Siemens Healthcare Diagnostics, Inc.
7.1.46 Tosoh Biosciences Corporation
7.1.47 Transgenomic, Inc.
7.1.48 Ventana Medical Systems, Inc.
7.1.49 Vermillion, Inc. (Formerly Ciphergen)
7.1.50 Vertex Pharmaceuticals, Inc.

Appendix 1: FDA Guidance for Industry: Pharmacogenomic Data Submissions
Appendix 1.1: Introduction
Appendix 1.2: Background
Appendix 1.3: Submission Policy
Appendix 1.3.1: General Principles
Appendix 1.3.2: Specific Uses of Pharmacogenomic Data in Drug Development and Labeling
Appendix 1.3.3: Benefits of Voluntary Submissions to Sponsors and FDA
Appendix 1.4: Submission of Pharmacogenomic Data
Appendix 1.4.1: Submission of Pharmacogenomic Data During the IND Phase
Appendix 1.4.2: Submission of Pharmacogenomic Data to a New NDA, BLA or Supplement
Appendix 1.4.3: Submission to a Previously Approved NDA or BLA
Appendix 1.4.4: Compliance with 21 CFR Part 58
Appendix 1.4.5: Submission of Voluntary Genomic Data from Application-Independent Research
Appendix 1.5: Format and Content of a VGDS
Appendix 1.6: Process for Submitting Pharmacogenomic Data
Appendix 1.7: Agency Review of VGDSs
Appendix 2: FDA Issues Draft Companion Diagnostic Guidance
Appendix 3: Histochemical Markers for Cancer
Appendix 4: E16 Biomarkers Related to Drug or Biotechnology Product Development: Context, Structure, and Format of Qualification Submissions
Appendix 4.1: Introduction
Appendix 4.2: Background
Appendix 4.3: Scope
Appendix 4.4: General Principles
Appendix 4.5: Structure of Biomarker Qualification Submissions
Appendix 5: Selected Personalized Medicine Drugs, Treatments and Diagnostics
Glossary

Index Of Figures
Figure 2.1: Strategic and Tactical Considerations for Co-Development of Companion Diagnostics
Figure 2.2: Global Market for Companion Diagnostics, 2012-2019
Figure 2.3: Number of Companion Diagnostic Agreements, 2000-2013
Figure 2.4: FDA Approved Companion Drugs by Type
Figure 3.1: From Genetic Content to Personalized Medicine
Figure 3.2: Impact of Diagnostic Testing on Healthcare Decision-Making
Figure 3.3: Impact of Diagnostic Testing on Healthcare Spending
Figure 3.4: Breakout of the Molecular Diagnostics Marketplace
Figure 3.5: Molecular Diagnostics Market Segmentation
Figure 3.6: Molecular Diagnostics Market Segmentation by Technology
Figure 3.7: Segmentation of the Personalized Medicine Market
Figure 4.1: Carcinogenesis is a Multi-Step Process
Figure 4.2: ASCO-CAP Guidelines for HER2 Testing in Breast Cancer: Equivocal Results with IHC
Figure 4.3: ASCO-CAP Guidelines for HER2 Testing in Breast Cancer: Results by FISH
Figure 5.1: Companion Diagnostics Partnering, 2007-2013
Figure 5.2: Companion Diagnostics Partnering by Stage of Development, 2013
Figure 5.3: Companion Diagnostics Partnering by Therapeutic Area, 2013
Figure 6.1: U.S. Healthcare Expenditures by Category of Service, 2010
Figure 6.2: Representation of the Trial-and-Error or One-Dose-Fits-All Approach vs. Personalized Medicine
Figure 6.3: Approaches to Personalized Medicine
Figure 6.4: Organizational Transformation to Support Personalized Medicine, 1998-2013
Figure 6.5: The Phase I and II Processes of Drug Metabolism
Figure 6.6: Hepatic Distribution of Human CYP450
Figure 6.7: Relative Contribution of CYP450 Enzymes to Drug Metabolism
Figure 6.8: Genetic Components Determine Drug Metabolism
Figure 6.9: Personalized Medicine Clinical Trials by Year, 1993-2008
Figure 6.10: Healthcare Value Chain

Index Of Tables
Table 2.1: FDA Approved Companion Diagnostic Devices: In Vitro and Imaging Tools
Table 2.2: Personalized Medicine Industry SWOT Analysis
Table 2.3: Hurdles to Personalized Medicine and Companion Diagnostics Development
Table 2.4: Timeline of Impact in Areas of Personalized Medicine
Table 2.5: Impact of Personalized Medicine on Various Therapeutic Areas
Table 3.1: Diagnostic Facts
Table 3.2: Timeline for Impact of Various Molecular Diagnostics Technologies on Personalized Medicine
Table 3.3: Impact of Molecular Diagnostics Technologies on Therapeutic Areas in Personalized Medicine
Table 3.4: Challenges of Various Molecular Diagnostics Technology Platforms in Personalized Medicine
Table 3.5: FDA Classification of Diagnostics by Risk
Table 4.1: Potential Benefits of Biomarkers as Companion Diagnostics
Table 4.2: Utility of Biomarker as Companion Diagnostics to Drug Development
Table 4.3: ASCO-CAP Guidelines for HER2 Testing in Breast Cancer: How to Interpret Test Results
Table 4.4: Myriad BRACAnalysis CDx™ Partnerships
Table 4.5: Drivers of Companion Diagnostics Discovery
Table 4.6: Barriers to Companion Diagnostics Discovery
Table 4.7: Device Submission Elements for the FDA
Table 5.1: List and Discounted Prices for Abbott Tumor Marker Tests
Table 5.2: Recent Major Companion Diagnostics Deals
Table 5.3: Summary of Biomarker Use in the Commercialization of Novel Oncology Pharmacotherapeutics
Table 5.4: Pharmacoeconomic Challenges to the Implementation of Biomarkers as Companion Diagnostics Tests
Table 6.1: Timeline for Development of Companion Diagnostics
Table 6.2: Personalized Medicine at the Nexus Point
Table 6.3: Percentage of Non-Responders in Various Drug Classes
Table 6.4: High-Profile Drug Withdrawals from the Marketplace
Table 6.5: Metabolism of Drugs by Hepatic Enzymes
Table 6.6: Drug Metabolism Drives Drug Efficacy/Toxicity
Table 6.7: Population Frequency of the Various Cytochromes
Table 6.8: Selected List of Personalized Medicine Tests
Table 6.9: Personalized Medicine and Companion Diagnostics Product Pipeline
Table 6.10: Members of the Personalized Medicine Coalition
Table 6.11: Typical Response Rates in Therapeutic Areas
Table 6.12: Prevalence of People Taking Medications Metabolized by Liver Enzymes
Table 6.13: UGT1A1 Helps to Determine Risks Associated with Irinotecan
Table 6.14: Current Product Labels: Enzyme Metabolism
Table 7.1: Major Players in Companion Diagnostics Sector and Summary List of Companion Diagnostics Agreements
Table 7.2: Major GeneChip Instrument Products
Table 7.3: Major GeneChip Array and Reagent Products
Table 7.4: Gene Titan Products
Table 7.5: Gene Atlas Products
Table 7.6: Opportunities for Biomarkers in Cancer Diagnosis and Treatment

Ordering:
Order Online - http://www.researchandmarkets.com/reports/591816/
Order by Fax - using the form below
Order by Post - print the order form below and send to
Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

<table>
<thead>
<tr>
<th>Product Name:</th>
<th>Companion Diagnostics in Personalized Medicine and Cancer Therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Web Address:</td>
<td><a href="http://www.researchandmarkets.com/reports/591816/">http://www.researchandmarkets.com/reports/591816/</a></td>
</tr>
<tr>
<td>Office Code:</td>
<td>SCDKT4LY</td>
</tr>
</tbody>
</table>

**Product Formats**
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) -</td>
<td></td>
</tr>
<tr>
<td>Single User:</td>
<td>USD 4000</td>
</tr>
<tr>
<td>1 - 10 Users:</td>
<td>USD 8000</td>
</tr>
<tr>
<td>Enterprisewide:</td>
<td>USD 12000</td>
</tr>
</tbody>
</table>

**Contact Information**
Please enter all the information below in **BLOCK CAPITALS**

<table>
<thead>
<tr>
<th>Title:</th>
<th>Mr</th>
<th>Mrs</th>
<th>Dr</th>
<th>Miss</th>
<th>Ms</th>
<th>Prof</th>
</tr>
</thead>
<tbody>
<tr>
<td>First Name:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Email Address: *</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Job Title:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Organisation:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Address:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>City:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Postal / Zip Code:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Country:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phone Number:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fax Number:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: 

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World